The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma
Published:
03/15/2024
An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of the body’s own immune cells to recognize and attack melanoma cells. In this webinar, hosted by Samantha Guild, JD, President of AIM at Melanoma, we explore the implications of this newly approved treatment for melanoma care with our guest, Dr. Allison Betof Warner, MD, PhD, a leading expert in TIL therapy.
CLICK on the image below to watch
Recent Posts
Mar. 03, 2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
Jan. 21, 2026